📊 GH Key Takeaways
Is GH a Good Investment? Thesis Analysis
Guardant Health faces severe financial distress with negative stockholders' equity of -$99.3M, indicating liabilities exceed assets by this amount. The company is burning cash at an alarming rate with negative operating cash flow of -$184.8M and negative free cash flow of -$233.1M, while generating negative net income of -$416.3M on flat revenue growth. Without significant operational improvements or capital injections, the company's financial viability is at critical risk despite maintaining adequate short-term liquidity.
Why Buy GH? Key Strengths
- Strong current ratio of 4.84x provides adequate short-term liquidity buffer
- Substantial cash reserves of $378.2M offer runway to fund operations in near term
- Position in medical diagnostics sector addresses important healthcare market needs
GH Investment Risks to Consider
- Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets
- Severe cash burn rate of -$233.1M in free cash flow is unsustainable; cash reserves deplete in ~1.6 years at current rate
- Persistent unprofitability with -44.5% operating margin and -42.4% net margin; zero revenue growth indicates market saturation or execution failure
- Negative interest coverage of -112.2x indicates inability to service debt obligations from operations
- Long-term debt of $1.5B represents 79% of total assets, creating refinancing risk if liquidity deteriorates
Key Metrics to Watch
- Operating cash flow trend - must turn positive to avoid insolvency
- Gross margin - need visibility into unit economics and pricing power
- Revenue growth acceleration - flat growth unsustainable given burn rate
- Path to EBITDA positive - critical to assess operational viability
- Debt covenant compliance - risk of default if leverage ratios breached
GH Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.84x current ratio provides a solid financial cushion.
GH Profitability Ratios
GH vs Healthcare Sector
How Guardant Health, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GH Overvalued or Undervalued?
Based on fundamental analysis, Guardant Health, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GH Balance Sheet & Liquidity
GH 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Guardant Health, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.28 indicates the company is currently unprofitable.
GH Growth Metrics (YoY)
GH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $191.5M | -$92.7M | $-0.74 |
| Q2 2025 | $177.2M | -$99.9M | $-0.80 |
| Q1 2025 | $168.5M | -$95.2M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GH Capital Allocation
GH SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Guardant Health, Inc. (CIK: 0001576280)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 23, 2026 | 4 | xslF345X06/wk-form4_1774297172.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/wk-form4_1773954975.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773870001.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773799065.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773799047.xml | View → |
❓ Frequently Asked Questions about GH
What is the AI rating for GH?
Guardant Health, Inc. (GH) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are GH's key strengths?
Claude: Strong current ratio of 4.84x provides adequate short-term liquidity buffer. Substantial cash reserves of $378.2M offer runway to fund operations in near term.
What are the risks of investing in GH?
Claude: Negative stockholders' equity indicates technical insolvency with liabilities exceeding assets. Severe cash burn rate of -$233.1M in free cash flow is unsustainable; cash reserves deplete in ~1.6 years at current rate.
What is GH's revenue and growth?
Guardant Health, Inc. reported revenue of $982.0M.
Does GH pay dividends?
Guardant Health, Inc. does not currently pay dividends.
Where can I find GH SEC filings?
Official SEC filings for Guardant Health, Inc. (CIK: 0001576280) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GH's EPS?
Guardant Health, Inc. has a diluted EPS of $-3.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GH a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Guardant Health, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GH stock overvalued or undervalued?
Valuation metrics for GH: ROE of N/A (sector avg: 15%), net margin of -42.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GH stock in 2026?
Our dual AI analysis gives Guardant Health, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GH's free cash flow?
Guardant Health, Inc.'s operating cash flow is $-184.8M, with capital expenditures of $48.3M. FCF margin is -23.7%.
How does GH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -42.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.84 (avg: 2).